Lung cancer and its operable brain metastasis: Survival rate and staging problems

József Furák, Imre Troján, Tamás Szöke, László Agócs, Attila Csekeö, Jözsef Kas, Egon Svastics, József Eller, László Tiszlavicz

Research output: Contribution to journalArticle

52 Citations (Scopus)


We assessed the survival rates regarding different stages of operable lung cancers causing operable brain metastasis in patients with or without cancer-related symptoms. The correlation between survival rates and the disease-free interval between lung surgery and metastasectomy was studied. Sixty-five patients were operated on for lung cancer and brain metastases. The disease-free interval was divided into 5 subgroups: 02 months, 35 months, 611 months, 1223 months, and 24 months and beyond. The study group comprised of patients with lung cancer in the following stages: 17 patients in stage I (1 patient in stage IA, 16 patients in stage IB), 16 patients in stage II (2 patients in stage IIA, 14 patients in stage IIB), 9 patients in stage IIIA, 4 patients in stage IIIB, and 19 patients in stage IV. Forty-four patients were symptom-free for lung cancer and 21 patients manifested lung cancer related symptoms. The 5-year survival rates were as follows: stage I = 22%, stage II = 20%, stage IIIA = 22%, stage IIIB = 0%, and stage IV = 23% after lung resections. There were no significant differences in the 5-year survival rates regarding the disease-free interval subgroups after brain metastasectomies (p = 0.19): disease-free interval 02 months = 22% and disease-free interval 24 months and beyond = 23%. The 5-year survival rate after metastasectomy was significantly greater (26% vs 5%) in patients without lung cancer related symptoms (p = 0.05). The 5-year survival rate in stage I, II, IIIA, and IV lung cancer with operable hematogenous brain metastases corresponds to that in the customary stage IIIA (23%). The disease-free interval exhibited no significant impact on the survival rate. The complaint-free status exhibits a significantly greater impact on the survival rate in hematogenic metastasis.

Original languageEnglish
Pages (from-to)241-247
Number of pages7
JournalAnnals of Thoracic Surgery
Issue number1
Publication statusPublished - Jan 1 2005



  • 10

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Furák, J., Troján, I., Szöke, T., Agócs, L., Csekeö, A., Kas, J., Svastics, E., Eller, J., & Tiszlavicz, L. (2005). Lung cancer and its operable brain metastasis: Survival rate and staging problems. Annals of Thoracic Surgery, 79(1), 241-247.